The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Outcome in a Prospective Phase II Trial of Medically Inoperable Stage I Non–Small-Cell Lung Cancer Patients Treated With Stereotactic Body Radiotherapy
Open accessAbstract
Purpose: The impact of stereotactic body radiotherapy (SBRT) on 3-year progression-free survival of medically inoperable patients with stage I non–small-cell lung cancer (NSCLC) was analyzed in a prospective phase II study. Patients and Methods: Fifty-seven patients with T1NOMO (70%) and T2N0M0 (30%) were included between August 2003 and September 2005 at seven different centers in Sweden, Norway, and Denmark and observed up to 36 months. SBRT was delivered with 15 Gy times three at the 67% isodose of the planning target volume. Results: Progression-free survival at 3 years was 52%. Overall- and cancer-specific survival at 1, 2, and 3 years was 86%, 65%, 60%, and 93%, 88%, 88%, respectively. There was no statistically significant difference in survival between patients with T1 or T2 tumors. At a median follow-up of 35 months (range, 4 to 47 months), 27 patients (47%) were deceased, seven as a result of lung cancer and 20 as a result of concurrent disease. Kaplan-Meier estimated local control at 3 years was 92%. Local relapse was observed in four patients (7%). Regional relapse was observed in three patients (5%). Nine patients (16%) developed distant metastases. The estimated risk of all failure (local, regional, or distant metastases) was increased in patients with T2 (41%) compared with those with T1 (18%) tumors (P = .027). Conclusion: With a 3-year local tumor control rate higher than 90% with limited toxicity, SBRT emerges as state-of-the-art treatment for medically inoperable stage I NSCLC and may even challenge surgery in operable instances.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Celli, B. R., Cote, C. G., Marin, J. M., Casanova, C., Montes de Oca, M., Mendez, R. A., Pinto Plata, V., & Cabral, H. J. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa021322 · Cited by 4,015
Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group.
Pignon, J.-P., Tribodet, H., Scagliotti, G. V., Douillard, J.-Y., Shepherd, F. A., Stephens, R. J., Dunant, A., Torri, V., Rosell, R., Seymour, L., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.9030 · Cited by 2,642
Timmerman, R., McGarry, R., Yiannoutsos, C., Papiez, L., Tudor, K., DeLuca, J., Ewing, M., Abdulrahman, R., DesRosiers, C., Williams, M., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.5937 · Cited by 1,556
Onishi, H., Shirato, H., Nagata, Y., Hiraoka, M., Fujino, M., 五味, 光., Niibe, Y., Karasawa, K., Hayakawa, K., Takai, Y., et al. (2007) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318074de34 · Cited by 989
Incidence of local recurrence and second primary tumors in resected stage I lung cancer
Martini, N., Bains, M. S., Burt, M. E., Zakowski, M. F., McCormack, P., Rusch, V. W., & Ginsberg, R. J. (1995) · The Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/s0022-5223(95)70427-2 · Cited by 973
Lagerwaard, F. J., Haasbeek, C. J. A., Smit, E. F., Slotman, B. J., & Senan, S. (2008) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2007.10.053 · Cited by 534
Stereotactic body radiation therapy of early-stage non–small-cell lung carcinoma: Phase I study
McGarry, R. C., Papiez, L., Williams, M., Whitford, T., & Timmerman, R. D. (2005) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2005.03.073 · Cited by 481
Bradley, J., Graham, M. V., Winter, K., Purdy, J. A., Komaki, R., Roa, W. H., Ryu, J. K., Bosch, W., & Emami, B. (2005) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2004.06.260 · Cited by 441
Mortality in GOLD stages of COPD and its dependence on symptoms of chronic bronchitis
Ekberg-Aronsson, M., Pehrsson, K., Nilsson, J.-Å., Nilsson, P. M., & Löfdahl, C.-G. (2005) · Respiratory Research · doi:10.1186/1465-9921-6-98 · Cited by 200
Predictors of Survival in COPD: More than Just the FEV1
Celli, B. R., Côté, C., Lareau, S. C., & Meek, P. (2008) · Respiratory Medicine · doi:10.1016/s0954-6111(08)70005-2 · Cited by 153
Cited by
Chang, J. Y., Liu, Y., Zhu, Z., Welsh, J. W., Gomez, D. R., Komaki, R., Roth, J. A., & Swisher, S. G. (2013) · Cancer · doi:10.1002/cncr.28217 · Cited by 91
“Diagnosis interval (range), mo 1 (0-6) 33 (7-210)”
Result
Metadata
- Authors
- Baumann, P., Nyman, J., Hoyer, M., Wennberg, B., Gagliardi, G., Lax, I., Drugge, N., Ekberg, L., Friesland, S., Johansson, K.-A., Lund, J.-Å., Morhed, E., Nilsson, K., Levin, N., Paludan, M., Sederholm, C., Traberg, A., Wittgren, L., & Lewensohn, R.
- Venue
- Journal of Clinical Oncology
- Published
- 2009-07-10
- Volume
- 27
- Issue
- 20
- Pages
- 3290-3296
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2112097252
- Cited by
- 836
- References
- 14
- FWCI
- 41.67
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Outcome in a Prospective Phase II Trial of Medically Inoperable Stage I Non–Small-Cell Lung Cancer Patients Treated With Stereotactic Body Radiotherapy. https://app.cochat.ai/papers/10.1200/jco.2008.21.5681
- The paper
- Baumann, P., Nyman, J., Hoyer, M., Wennberg, B., Gagliardi, G., Lax, I., Drugge, N., Ekberg, L., Friesland, S., Johansson, K.-A., Lund, J.-Å., Morhed, E., Nilsson, K., Levin, N., Paludan, M., Sederholm, C., Traberg, A., Wittgren, L., & Lewensohn, R. (2009). Outcome in a Prospective Phase II Trial of Medically Inoperable Stage I Non–Small-Cell Lung Cancer Patients Treated With Stereotactic Body Radiotherapy. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2008.21.5681
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
